Senesco Technologies Inc (SNTI) 1.7000 $SNTI
Senesco Announces Corporate Rebranding to Sevion Therapeutics
Business Wire - Tue Sep 09, 7:15AM CDT
Senesco Technologies, Inc. (OTCQB:SNTI) (the "Company" or "Sevion"
, a clinical-stage company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, announced today a corporate rebranding under which the Company will change its name to Sevion Therapeutics, Inc. The Company will continue to trade as SNTI until a new ticker symbol is obtained. The rebranding and new corporate identity are first steps in fulfilling the Company's goal of becoming a preeminent, next-generation biologics company with best- and first-in-class product candidates and technologies.
Senesco concludes patient admission in Phase 1b/2a SNS01-T Study in B-cell cancers
M2 - Mon Sep 01, 5:15AM CDT
Biotech company Senesco Technologies (OTC BB:SNTI) revealed on Friday the completion of enrollment in its ongoing Phase 1b/2a open-label, multiple-dose, dose-escalation clinical trial of SNS01-T in patients with relapsed or refractory multiple myeloma, plasma cell leukemia or B cell lymphoma.
Senesco Closes Enrollment in Its Phase 1b/2a SNS01-T Study
Business Wire - Fri Aug 29, 7:15AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company" (OTCQB:SNTI) today announced the closing of enrollment in its ongoing Phase 1b/2a open-label, multiple-dose, dose-escalation clinical trial of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A), in patients with relapsed or refractory multiple myeloma, plasma cell leukemia or B cell lymphoma.
Senesco names Ronald A. Martell as new CEO
M2 - Thu Jun 26, 4:54AM CDT
Biotech company Senesco Technologies (OTC BB:SNTI) revealed on Wednesday the election of Ronald A. Martell as chief executive officer at the 2014 BIO International Convention in San Diego.
Senesco Presents Company Update at 2014 BIO International Convention
Business Wire - Wed Jun 25, 1:05PM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company" (OTCQB:SNTI) provided an overview of the company's current research and development status at the 2014 BIO International Convention in San Diego. Acting CEO, Vaughn V. Smider, M.D., Ph.D., presented the update, including the announcement of the completion of the administrative and financial integration of Fabrus with Senesco. The presentation will also be released in an 8-K filing and can be accessed via the company's website.
Senesco Technologies, Inc. - "Reconsidering the Entire Cancer Treatment Approach"
ACCESSWIRE - Tue Apr 01, 10:47AM CDT
BRIDGEWATER, NJ / ACCESSWIRE / April 1, 2014 / Senesco Technologies, Inc. (OTCQB: SNTI) today published a new blog post on The Chairman's Blog, written by the Company's President and CEO, Dr. Leslie J. Browne. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Senesco Opens Two New Clinical Trial Sites and Initiates Treatment of the First Patient in South Africa
Business Wire - Wed Mar 12, 7:15AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company" (OTCQB:SNTI) reported the opening of two new sites in the Republic of South Africa at Pretoria East Hospital and Groote Schuur Hospital in Cape Town. Treatment of the first patient in South Africa has been initiated in Senesco's Phase 1b/2a clinical study of its product candidate, SNS01-T.
Senesco pays off line of credit held by JMP Securities
M2 - Tue Mar 11, 9:34AM CDT
Senesco Technologies Inc (OTCBB:SNTI), a clinical-stage biotech company specializing in cancer therapeutics, announced on Monday that is has paid in full and cancelled the line of credit held by JMP Securities.
Senesco Pays Off Line of Credit
Business Wire - Mon Mar 10, 7:15AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company" (OTCQB: SNTI) announces that is has paid in full and canceled the line of credit held by JMP Securities (the "Line of Credit" .
Dean Foods Reports Fourth Quarter And Full Year 2013 Results
PR Newswire - Tue Feb 11, 7:00AM CST
Dean Foods Company (NYSE: DF) today announced that the Company earned $8.58 per diluted share for the full year 2013, as compared to $1.70 per diluted share for the full year 2012. Full year 2013 reported results include the gain on disposition of WhiteWave common stock of $416 million, the gain on sale of Morningstar of $492 million (net of tax) and other one-time or non-recurring items, as more fully described in the attached tables. On an adjusted basis, the Company earned $0.86 per diluted share for the full year 2013, compared to $0.77 for the full year 2012.
Senesco signs Letter of Intent to merge with Fabrus
M2 - Tue Dec 31, 3:58AM CST
Senesco Technologies Inc (OTCBB:SNTI), a clinical-stage biotech company specialising in cancer therapeutics, announced on Monday that it has agreed to terms and executed a non-binding Letter of Intent to merge with Fabrus Inc, a privately-held biotechnology company.
Senesco Technologies Reports Fiscal Year 2013 Financial Results
Business Wire - Thu Sep 12, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company" (OTCQB:SNTI) today announced financial results for the 12 months ended June 30, 2013 ("Fiscal 2013" .
OTC Daily Alert Stock Watch - Senesco Technologies, Inc. (OTCQB:SNTI)
WorldStockWire - Wed Aug 07, 2:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Senesco Announces Results of Cohort 2 of its SNS01-T Phase 1b/2a Trial
Business Wire - Wed Jun 19, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company" (OTC QB: SNTI) reported results of cohort 2 in its Phase 1b/2a clinical study of SNS01-T.
Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results
Business Wire - Thu May 16, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company" (OTCQB: SNTI) today reported financial results for the third quarter of fiscal year 2013 which ended on March 31, 2013.
Senesco Technologies Inc expects USD1.255m in equity financing
M2 - Fri May 10, 12:59PM CDT
Cancer therapy company Senesco Technologies Inc (OTC BB:SNTI) revealed on Thursday the execution of a USD1.255m securities purchase agreement with certain institutional investors.
Senesco Announces Start of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma
Business Wire - Mon May 06, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company" (OTC QB: SNTI) reported today that the Data Review Committee (DRC) for its SNS01-T trial in multiple myeloma and non-Hodgkins B-cell lymphoma approved initiating cohort 3 and escalating the SNS01-T dose level four-fold to 0.2 mg/Kg. The DRC's review of the results of cohort 2 concluded that SNS01-T was safe and well tolerated at a dose of 0.05 mg/Kg. No drug-related serious adverse events or dose limiting toxicities were observed in either of the first two cohorts.
Senesco Announces Completion of Cohort 2 of its Phase 1b/2a Trial
Business Wire - Mon Apr 22, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company" (OTC QB: SNTI) reported today that it has completed cohort 2 in its Phase 1b/2a clinical study of SNS01-T.
Senesco Provides Management Update
Business Wire - Mon Apr 08, 8:15AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company" (OTC:SNTI) today announced that Leslie J. Browne, Ph.D., the Company's President and Chief Executive Officer, is being treated for a medical condition that may limit his time to travel and attend public events. However, Dr. Browne will continue with his day-to-day duties and responsibilities as President and CEO of the Company. The Senesco Board has agreed to assist Dr. Browne with certain activities, including Harlan Waksal, M.D., Chairman of Senesco, who will take the lead on certain public activities like investor relations. The Board will continue to monitor Dr. Browne's responsibilities as his treatment progresses.
REIT Companies Join to Webcast Live for Special March 7th RetailInvestorConferences.com Event
CNW Group - Tue Mar 05, 12:14PM CST
Live, online webcasts presentations allow investors to ask questions in real-time and "chat" in virtual trade booths
Senesco Announces Corporate Rebranding to Sevion Therapeutics
Business Wire - Tue Sep 09, 7:15AM CDT
Senesco Technologies, Inc. (OTCQB:SNTI) (the "Company" or "Sevion"
, a clinical-stage company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, announced today a corporate rebranding under which the Company will change its name to Sevion Therapeutics, Inc. The Company will continue to trade as SNTI until a new ticker symbol is obtained. The rebranding and new corporate identity are first steps in fulfilling the Company's goal of becoming a preeminent, next-generation biologics company with best- and first-in-class product candidates and technologies. Senesco concludes patient admission in Phase 1b/2a SNS01-T Study in B-cell cancers
M2 - Mon Sep 01, 5:15AM CDT
Biotech company Senesco Technologies (OTC BB:SNTI) revealed on Friday the completion of enrollment in its ongoing Phase 1b/2a open-label, multiple-dose, dose-escalation clinical trial of SNS01-T in patients with relapsed or refractory multiple myeloma, plasma cell leukemia or B cell lymphoma.
Senesco Closes Enrollment in Its Phase 1b/2a SNS01-T Study
Business Wire - Fri Aug 29, 7:15AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"
(OTCQB:SNTI) today announced the closing of enrollment in its ongoing Phase 1b/2a open-label, multiple-dose, dose-escalation clinical trial of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A), in patients with relapsed or refractory multiple myeloma, plasma cell leukemia or B cell lymphoma. Senesco names Ronald A. Martell as new CEO
M2 - Thu Jun 26, 4:54AM CDT
Biotech company Senesco Technologies (OTC BB:SNTI) revealed on Wednesday the election of Ronald A. Martell as chief executive officer at the 2014 BIO International Convention in San Diego.
Senesco Presents Company Update at 2014 BIO International Convention
Business Wire - Wed Jun 25, 1:05PM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"
(OTCQB:SNTI) provided an overview of the company's current research and development status at the 2014 BIO International Convention in San Diego. Acting CEO, Vaughn V. Smider, M.D., Ph.D., presented the update, including the announcement of the completion of the administrative and financial integration of Fabrus with Senesco. The presentation will also be released in an 8-K filing and can be accessed via the company's website. Senesco Technologies, Inc. - "Reconsidering the Entire Cancer Treatment Approach"
ACCESSWIRE - Tue Apr 01, 10:47AM CDT
BRIDGEWATER, NJ / ACCESSWIRE / April 1, 2014 / Senesco Technologies, Inc. (OTCQB: SNTI) today published a new blog post on The Chairman's Blog, written by the Company's President and CEO, Dr. Leslie J. Browne. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Senesco Opens Two New Clinical Trial Sites and Initiates Treatment of the First Patient in South Africa
Business Wire - Wed Mar 12, 7:15AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"
(OTCQB:SNTI) reported the opening of two new sites in the Republic of South Africa at Pretoria East Hospital and Groote Schuur Hospital in Cape Town. Treatment of the first patient in South Africa has been initiated in Senesco's Phase 1b/2a clinical study of its product candidate, SNS01-T. Senesco pays off line of credit held by JMP Securities
M2 - Tue Mar 11, 9:34AM CDT
Senesco Technologies Inc (OTCBB:SNTI), a clinical-stage biotech company specializing in cancer therapeutics, announced on Monday that is has paid in full and cancelled the line of credit held by JMP Securities.
Senesco Pays Off Line of Credit
Business Wire - Mon Mar 10, 7:15AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"
(OTCQB: SNTI) announces that is has paid in full and canceled the line of credit held by JMP Securities (the "Line of Credit" . Dean Foods Reports Fourth Quarter And Full Year 2013 Results
PR Newswire - Tue Feb 11, 7:00AM CST
Dean Foods Company (NYSE: DF) today announced that the Company earned $8.58 per diluted share for the full year 2013, as compared to $1.70 per diluted share for the full year 2012. Full year 2013 reported results include the gain on disposition of WhiteWave common stock of $416 million, the gain on sale of Morningstar of $492 million (net of tax) and other one-time or non-recurring items, as more fully described in the attached tables. On an adjusted basis, the Company earned $0.86 per diluted share for the full year 2013, compared to $0.77 for the full year 2012.
Senesco signs Letter of Intent to merge with Fabrus
M2 - Tue Dec 31, 3:58AM CST
Senesco Technologies Inc (OTCBB:SNTI), a clinical-stage biotech company specialising in cancer therapeutics, announced on Monday that it has agreed to terms and executed a non-binding Letter of Intent to merge with Fabrus Inc, a privately-held biotechnology company.
Senesco Technologies Reports Fiscal Year 2013 Financial Results
Business Wire - Thu Sep 12, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"
(OTCQB:SNTI) today announced financial results for the 12 months ended June 30, 2013 ("Fiscal 2013" . OTC Daily Alert Stock Watch - Senesco Technologies, Inc. (OTCQB:SNTI)
WorldStockWire - Wed Aug 07, 2:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Senesco Announces Results of Cohort 2 of its SNS01-T Phase 1b/2a Trial
Business Wire - Wed Jun 19, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"
(OTC QB: SNTI) reported results of cohort 2 in its Phase 1b/2a clinical study of SNS01-T. Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results
Business Wire - Thu May 16, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"
(OTCQB: SNTI) today reported financial results for the third quarter of fiscal year 2013 which ended on March 31, 2013. Senesco Technologies Inc expects USD1.255m in equity financing
M2 - Fri May 10, 12:59PM CDT
Cancer therapy company Senesco Technologies Inc (OTC BB:SNTI) revealed on Thursday the execution of a USD1.255m securities purchase agreement with certain institutional investors.
Senesco Announces Start of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma
Business Wire - Mon May 06, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"
(OTC QB: SNTI) reported today that the Data Review Committee (DRC) for its SNS01-T trial in multiple myeloma and non-Hodgkins B-cell lymphoma approved initiating cohort 3 and escalating the SNS01-T dose level four-fold to 0.2 mg/Kg. The DRC's review of the results of cohort 2 concluded that SNS01-T was safe and well tolerated at a dose of 0.05 mg/Kg. No drug-related serious adverse events or dose limiting toxicities were observed in either of the first two cohorts. Senesco Announces Completion of Cohort 2 of its Phase 1b/2a Trial
Business Wire - Mon Apr 22, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"
(OTC QB: SNTI) reported today that it has completed cohort 2 in its Phase 1b/2a clinical study of SNS01-T. Senesco Provides Management Update
Business Wire - Mon Apr 08, 8:15AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"
(OTC:SNTI) today announced that Leslie J. Browne, Ph.D., the Company's President and Chief Executive Officer, is being treated for a medical condition that may limit his time to travel and attend public events. However, Dr. Browne will continue with his day-to-day duties and responsibilities as President and CEO of the Company. The Senesco Board has agreed to assist Dr. Browne with certain activities, including Harlan Waksal, M.D., Chairman of Senesco, who will take the lead on certain public activities like investor relations. The Board will continue to monitor Dr. Browne's responsibilities as his treatment progresses. REIT Companies Join to Webcast Live for Special March 7th RetailInvestorConferences.com Event
CNW Group - Tue Mar 05, 12:14PM CST
Live, online webcasts presentations allow investors to ask questions in real-time and "chat" in virtual trade booths
